U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of...

Related Keywords

Michigan ,United States ,New York ,Ohio ,America ,Dermatol Clin ,Thomas Hudson ,Emma Guttman Yassky ,Instagram ,National Eczema Association ,Linkedin ,Twitter ,Drug Administration ,Exchange Commission ,Public Health Burden ,Icahn School Of Medicine At Mount Sinai ,Allergan ,University Of Michigan Medicine ,Facebook ,Abbvie Inc ,Waldman Professor ,System Chair ,Icahn School ,Mount Sinai ,New York City ,Eczema Area ,Investigator Global Assessment ,Atopic Dermatitis ,Worst Pruritus Numerical Rating Scale ,Worst Pruritus ,Abbvie Assist ,Julie Block ,National Eczema ,Important Safety ,Mississippi River ,Full Prescribing Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,North Chicago ,Global Epidemiology ,Ann Nutr Metab ,Rev Dis Primers ,Health Burden ,America Study ,Cross Sectional Study Examining ,Disease Burden ,Study Comparing Upadacitinib ,Adults With Rheumatoid Arthritis ,Stable Dose ,Who Have ,Inadequate Response ,Adult Patients With Moderate ,Severe Atopic Dermatitis ,Participants With Psoriatic Arthritis Who Have ,Evaluate Efficacy ,Adult Participants With Axial Spondyloarthritis ,Participants With Moderately ,Severely Active Crohn ,Disease Who Have Inadequately Responded ,Are Intolerant ,Maintenance Therapy ,Severely Active Ulcerative Colitis ,Participants With Giant Cell Arteritis ,Subjects With Takayasu Arteritis ,Abbvie ,